Jefferies Group LLC Editas Medicine, Inc. Put Options Transaction History

Jefferies Group LLC

  • $10.2 Billion
  • Q3 2022

Put Options

11 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2022

Sep 21, 2023
BUY
$14.08 - $27.63 $573,056 - $1.12 Million
40,700 Added 54.41%
115,500 $2.2 Million
Q1 2022

May 16, 2022
BUY
$14.08 - $27.63 $573,056 - $1.12 Million
40,700 Added 54.41%
115,500 $2.2 Million
Q4 2021

Sep 21, 2023
BUY
$26.55 - $40.57 $1.11 Million - $1.7 Million
41,900 Added 127.36%
74,800 $1.99 Million
Q4 2021

Feb 14, 2022
BUY
$26.55 - $40.57 $1.11 Million - $1.7 Million
41,900 Added 127.36%
74,800 $1.99 Million
Q3 2021

Sep 21, 2023
BUY
$39.27 - $72.94 $361,284 - $671,048
9,200 Added 38.82%
32,900 $1.35 Million
Q3 2021

Nov 15, 2021
BUY
$39.27 - $72.94 $361,284 - $671,048
9,200 Added 38.82%
32,900 $1.35 Million
Q2 2021

Sep 21, 2023
SELL
$31.29 - $56.64 $616,413 - $1.12 Million
-19,700 Reduced 45.39%
23,700 $1.34 Million
Q2 2021

Aug 20, 2021
SELL
$31.29 - $56.64 $73.4 Million - $133 Million
-2,346,300 Reduced 99.0%
23,700 $1.34 Million
Q2 2021

Aug 16, 2021
BUY
$31.29 - $56.64 $72.8 Million - $132 Million
2,326,600 Added 5360.83%
2,370,000 $1.34 Million
Q1 2021

Sep 21, 2023
SELL
$39.71 - $90.58 $2.86 Million - $6.53 Million
-72,100 Reduced 62.42%
43,400 $1.82 Million
Q1 2021

May 14, 2021
BUY
$39.71 - $90.58 $1.72 Million - $3.93 Million
43,400 New
43,400 $1.82 Million

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $183M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email